The Food and Drug Administration on Friday approved Novartis' Adakveo to prevent blood-vessel blockages in patients with sickle cell anemia that can be painful and sometimes fatal.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,